BioCentury | Aug 20, 2020
Finance

Inhibrx, Harmony debut on NASDAQ as JW, Harbour line up on HKEX

...platform to discover mAbs with Mount Sinai Health System under a March deal. Elizabeth S. Eaton Inhibrx Inc. Harmony Biosciences Harbour...
BioCentury | Aug 14, 2020
Finance

Aug. 13 Quick Takes: Qiagen shareholders opt for independence; plus IPO terms from Inhibrx, Harmony and more from Biohaven-Royalty, Scioto, Bodyport, immunoSCAPE

...$606.1 million. It is developing single domain antibodies to treat cancer and orphan and infectious diseases.Harmony Biosciences...
...T cell responses to COVID-19. BC Staff Nurtec ODT, rimegepant (BHV-3000, bms-927711) Zavegepant (BHV-3500) Qiagen N.V. Thermo Fisher Scientific Inc. Inhibrx Inc. Harmony Biosciences LLC Biohaven...
BioCentury | Jul 30, 2020
Finance

July 28 Quick Takes: Venture round reveals for Omega, Praxis, HaiHe; plus trio of NASDAQ IPO filings, Atsena’s debut, La Jolla-Tetraphase

...is developing single domain antibodies to treat cancer and orphan and infectious diseases. Neurology company Harmony Biosciences...
...Targets GUCY2D - Guanylate cyclase 2D membrane retina-specific BioCentury Staff Sanofi University of Florida Praxis Precision Medicines Inc. CureVac AG Inhibrx Harmony Biosciences LLC Guanylate...
BioCentury | Dec 4, 2019
Clinical News

Axsome plans Phase III trial for narcolepsy therapy following positive Phase II data

...to inquiries about whether AXS-12 would be scheduled. In August, FDA approved Wakix pitolisant from Harmony Biosciences LLC...
BioCentury | Aug 15, 2019
Company News

Harmony crosses finish line with Wakix for narcolepsy

...drug. During 2017-18, Harmony raised $295 million to push it through registration. In October 2017, Harmony Biosciences LLC...
...Histamine H3 receptor Elizabeth S. Eaton, Staff Writer Wakix (Brand), BF2.649 (Compound #), pitolisant (Generic), Wakix (Other) Harmony Biosciences LLC Histamine...
BioCentury | Apr 22, 2019
Company News

Management tracks: MeiraGTx, Retrophin, Aduro

...rare genetic dermatology company Castle Creek Pharmaceuticals LLC (Parsippany, N.J.) and rare CNS disorders company Harmony Biosciences LLC...
BioCentury | Oct 13, 2017
Financial News

Harmony raises $270M, licenses narcolepsy drug

...On Oct. 6, CNS company Harmony Biosciences LLC (Plymouth Meeting, Pa.) said it raised $270 million in an...
...is a subsidiary of Paragon Biosciences LLC (Chicago, Ill.). Harmony Biosciences LLC , Plymouth Meeting, Pa. Elizabeth S. Eaton BF2.649 pitolisant Bioprojet Harmony Biosciences LLC Histamine...
BioCentury | Oct 6, 2017
Financial News

Harmony raises $270M, licenses narcolepsy drug

...CNS company Harmony Biosciences LLC (Plymouth Meeting, Pa.) said it raised $270 million in an equity round from...
...in its pipeline. Harmony is a subsidiary of Paragon Biosciences LLC. Elizabeth S. Eaton pitolisant Bioprojet Histamine H3 receptor (HRH3) Harmony Biosciences LLC Paragon...
Items per page:
1 - 8 of 8
BioCentury | Aug 20, 2020
Finance

Inhibrx, Harmony debut on NASDAQ as JW, Harbour line up on HKEX

...platform to discover mAbs with Mount Sinai Health System under a March deal. Elizabeth S. Eaton Inhibrx Inc. Harmony Biosciences Harbour...
BioCentury | Aug 14, 2020
Finance

Aug. 13 Quick Takes: Qiagen shareholders opt for independence; plus IPO terms from Inhibrx, Harmony and more from Biohaven-Royalty, Scioto, Bodyport, immunoSCAPE

...$606.1 million. It is developing single domain antibodies to treat cancer and orphan and infectious diseases.Harmony Biosciences...
...T cell responses to COVID-19. BC Staff Nurtec ODT, rimegepant (BHV-3000, bms-927711) Zavegepant (BHV-3500) Qiagen N.V. Thermo Fisher Scientific Inc. Inhibrx Inc. Harmony Biosciences LLC Biohaven...
BioCentury | Jul 30, 2020
Finance

July 28 Quick Takes: Venture round reveals for Omega, Praxis, HaiHe; plus trio of NASDAQ IPO filings, Atsena’s debut, La Jolla-Tetraphase

...is developing single domain antibodies to treat cancer and orphan and infectious diseases. Neurology company Harmony Biosciences...
...Targets GUCY2D - Guanylate cyclase 2D membrane retina-specific BioCentury Staff Sanofi University of Florida Praxis Precision Medicines Inc. CureVac AG Inhibrx Harmony Biosciences LLC Guanylate...
BioCentury | Dec 4, 2019
Clinical News

Axsome plans Phase III trial for narcolepsy therapy following positive Phase II data

...to inquiries about whether AXS-12 would be scheduled. In August, FDA approved Wakix pitolisant from Harmony Biosciences LLC...
BioCentury | Aug 15, 2019
Company News

Harmony crosses finish line with Wakix for narcolepsy

...drug. During 2017-18, Harmony raised $295 million to push it through registration. In October 2017, Harmony Biosciences LLC...
...Histamine H3 receptor Elizabeth S. Eaton, Staff Writer Wakix (Brand), BF2.649 (Compound #), pitolisant (Generic), Wakix (Other) Harmony Biosciences LLC Histamine...
BioCentury | Apr 22, 2019
Company News

Management tracks: MeiraGTx, Retrophin, Aduro

...rare genetic dermatology company Castle Creek Pharmaceuticals LLC (Parsippany, N.J.) and rare CNS disorders company Harmony Biosciences LLC...
BioCentury | Oct 13, 2017
Financial News

Harmony raises $270M, licenses narcolepsy drug

...On Oct. 6, CNS company Harmony Biosciences LLC (Plymouth Meeting, Pa.) said it raised $270 million in an...
...is a subsidiary of Paragon Biosciences LLC (Chicago, Ill.). Harmony Biosciences LLC , Plymouth Meeting, Pa. Elizabeth S. Eaton BF2.649 pitolisant Bioprojet Harmony Biosciences LLC Histamine...
BioCentury | Oct 6, 2017
Financial News

Harmony raises $270M, licenses narcolepsy drug

...CNS company Harmony Biosciences LLC (Plymouth Meeting, Pa.) said it raised $270 million in an equity round from...
...in its pipeline. Harmony is a subsidiary of Paragon Biosciences LLC. Elizabeth S. Eaton pitolisant Bioprojet Histamine H3 receptor (HRH3) Harmony Biosciences LLC Paragon...
Items per page:
1 - 8 of 8